A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials

L Sforzini, C Worrell, M Kose, IM Anderson… - Molecular …, 2022 - nature.com
Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD)
as subtypes of major depressive disorder (MDD) are not unequivocally defined. In the …

The Hamilton rating scales for depression: a critical review of clinimetric properties of different versions

D Carrozzino, C Patierno, GA Fava… - Psychotherapy and …, 2020 - karger.com
The format of the original Hamilton Rating Scale for Depression (HAM-D) was unstructured:
only general instructions were provided for rating individual items. Over the years, a number …

Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized …

V Popova, EJ Daly, M Trivedi… - American Journal of …, 2019 - Am Psychiatric Assoc
Objective: About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants. This study compared the efficacy and safety of …

Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial

EJ Daly, MH Trivedi, A Janik, H Li, Y Zhang, X Li… - JAMA …, 2019 - jamanetwork.com
Importance Controlled studies have shown short-term efficacy of esketamine for treatment-
resistant depression (TRD), but long-term effects remain to be established. Objective To …

Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double …

M Fedgchin, M Trivedi, EJ Daly… - International Journal …, 2019 - academic.oup.com
Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …

Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial

EJ Daly, JB Singh, M Fedgchin, K Cooper, P Lim… - JAMA …, 2018 - jamanetwork.com
Importance Approximately one-third of patients with major depressive disorder (MDD) do not
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …

[HTML][HTML] Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3

R Ochs-Ross, EJ Daly, Y Zhang, R Lane, P Lim… - The American Journal of …, 2020 - Elsevier
Background Elderly patients with major depression have a poorer prognosis, are less
responsive to treatment, and show greater functional decline compared with younger …

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

CL Raison, RE Rutherford, BJ Woolwine… - JAMA …, 2013 - jamanetwork.com
Context Increased concentrations of inflammatory biomarkers predict antidepressant
nonresponse, and inflammatory cytokines can sabotage and circumvent the mechanisms of …

Binge-eating disorder in adults: a systematic review and meta-analysis

KA Brownley, ND Berkman, CM Peat… - Annals of internal …, 2016 - acpjournals.org
Background: The best treatment options for binge-eating disorder are unclear. Purpose: To
summarize evidence about the benefits and harms of psychological and pharmacologic …

[HTML][HTML] Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study

JB Singh, M Fedgchin, E Daly, L Xi, C Melman… - Biological …, 2016 - Elsevier
Background The purpose of this study was to assess the efficacy and safety and to explore
the dose response of esketamine intravenous (IV) infusion in patients with treatment …